| what is the better treatment for single digit dupuytren's contracture: surgical release or collagenase clostridium histolyticum (xiapex) injection? | the purpose of this study was to compare the initial and final outcome range of motion in the mcp-j and pip-j of single digit dupuytren's contracture treated with either open surgical excision or manipulation after collagenase clostridium histolyticum (cch; xiapex) injection. | 2014 | 25155703 |
| collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice. | to collect data on the real-world effectiveness of collagenase clostridium histolyticum (cch) during its first year of use following u.s. food and drug administration approval and compare those results with clinical trial efficacy data. | 2013 | 24140362 |
| use of resources and costs associated with the treatment of dupuytren's contracture at an orthopedics and traumatology surgery department in denia (spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. | our purpose was to analyze and compare the use of direct health resources and costs generated in the treatment of dupuytren's contracture using two different techniques: subtotal fasciectomy and infiltration with collagenase clostridium histolyticum (cch) in regular clinical practice at the orthopedic and traumatology surgery (ots) department at the hospital de denia (spain). | 2013 | 24125161 |
| cold intolerance following collagenase clostridium histolyticum treatment for dupuytren contracture: a molecular mechanism. | | 2014 | 25154579 |
| peyronie's disease: review and recent advances. | peyronie's disease is an incurable, sexually debilitating fibrotic disease of the penis that results in penile curvature, coital failure, and significant psychological stress for patients and their partners. appropriate treatment should be individualized and tailored to the patient's goals and expectations, disease history, physical exam findings, and erectile function. while medical treatments exist, there is little evidence to support their use. high-quality data supporting more recent advance ... | 2014 | 24984940 |
| first identification of resident and circulating fibrocytes in dupuytren's disease shown to be inhibited by serum amyloid p and xiapex. | dupuytren's disease (dd) is a common progressive fibroproliferative disorder causing permanent digital contracture. proliferative myofibroblasts are thought to be the cells responsible for dd initiation and recurrence, although their source remains unknown. dd tissue has also been shown to harbor mesenchymal and hematopoietic stem cells. fibrocytes are circulating cells that show characteristics of fibroblasts and they express surface markers for both hematopoietic and mesenchymal stromal cells. ... | 2014 | 24933153 |
| resource utilisation associated with single digit dupuytren's contracture treated with either surgery or injection of collagenase clostridium histolyticum. | the gold standard treatment for dupuytren's contracture is surgical excision of the cord. a non-surgical treatment with collagenase clostridium histolyticum injection is available but appears costly. | 2014 | 24875504 |
| acceleration of bone union after structural bone grafts with a collagen-binding basic fibroblast growth factor anchored-collagen sheet for critical-size bone defects. | bone allografts are commonly used for the repair of critical-size bone defects. however, the loss of cellular activity in processed grafts markedly reduces their healing potential compared with autografts. to overcome this obstacle, we developed a healing system for critical-size bone defects that consists of overlaying an implanted bone graft with a collagen sheet (cs) loaded with basic fibroblast growth factor (bfgf) fused to the collagen-binding domain derived from a clostridium histolyticum ... | 2014 | 24844188 |
| bioactive chitosan nanoparticles and photodynamic therapy inhibit collagen degradation in vitro. | collagen is the major structural protein of human dentin. degradation of collagen by bacterial enzymes can facilitate microbial penetration, compromise structural/interfacial integrity, and lower resistance to fracture of dentin. we evaluated the ability of photodynamic therapy (pdt), bioactive chitosan nanoparticles (csnp), or pdt in combination with csnp to inhibit bacterial collagenase-mediated degradation of collagen. | 2014 | 24767568 |
| treatment of dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system. | clinical trials seeking to establish long-term efficacy of injectable collagenase clostridium histolyticum for treatment of dupuytren disease are ongoing. in this quality improvement study, the efficacy, recurrence rate, and complications of collagenase injection for dupuytren disease are reviewed in a population of veteran patients. | 2014 | 24741384 |
| acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (xiapex) for dupuytren's contracture. | we report a case of acute (24 h) double flexor tendon rupture of the little finger after a single injection of collagenase clostridium histolyticum into a palmar dupuytren's contracture cord which caused metacarpophalangeal joint contracture. tendon surgery was performed 48 h postinjury with primary repair and standard rehabilitation but it resulted in poor active flexion due to adhesions. previous papers have suggested that a needle inserted into the flexor tendon can be detected prior to the i ... | 2014 | 24729115 |
| early outcomes of a sequential series of 144 patients with dupuytren's contracture treated by collagenase injection using an increased dose, multi-cord technique. | collagenase clostridium histolyticum is the first and only united states food and drug association approved nonsurgical treatment for patients with a palpable dupuytren's contracture cord. however, the food and drug association has only approved injection of 0.58 mg of this enzyme into one palpable dupuytren's contracture cord at a time. this review reports on the early outcome of 144 patients treated with the entire bottle of enzyme, approximately 0.78 mg, along with use of a novel slow intraco ... | 2015 | 24698852 |
| safety and tolerability of collagenase clostridium histolyticum and fasciectomy for dupuytren's contracture. | safety was evaluated for collagenase clostridium histolyticum (cch) based on 11 clinical trials (n = 1082) and compared with fasciectomy data in a structured literature review of 48 european studies (n = 7727) for treatment of dupuytren's contracture. incidence of adverse events was numerically lower with cch vs. equivalent complications from fasciectomy (median [range] incidence), including nerve injury (0% vs. 3.8% [0%-50+%]), neurapraxia (4.4% vs. 9.4% [0%-51.3%]), complex regional pain syndr ... | 2015 | 24698851 |
| the 32nd annual j.p. morgan healthcare conference (january 13-16, 2014 - san francisco, california, usa): auxilium pharmaceuticals. | ceo and president adrian adams described auxilium pharmaceuticals as "the same as a big pharma company, only smaller." this 'specialty biopharmaceutical company' has transformed itself in the last 6 to 9 months to become the "leading men's healthcare franchise with a broad and diverse product portfolio." all of this has led to a very busy 2013, which began with the usd 600 million acquisition (q2) and integration of actient pharmaceuticals, the licensing of avanafil (stendra™) for erectile dysfu ... | 2014 | 24696871 |
| cold intolerance following collagenase clostridium histolyticum treatment for dupuytren contracture. | | 2014 | 24679915 |
| collagenase clostridium histolyticum in patients with dupuytren's contracture: results from point x, an open-label study of clinical and patient-reported outcomes. | in point x, a study designed to reflect clinical practice and patient treatment choices, 254 european patients received open-label collagenase for dupuytren's contracture. the most severely affected joint was treated first in 74% of patients. in total, 52%, 41%, 7%, and 1% of patients selected the little, ring, middle, and index finger, respectively; 79% had one or two joints treated. only 9% of patients (n = 24) received 4 or 5 injections. the mean improvement in total passive extension deficit ... | 2015 | 24470559 |
| minimally invasive treatment of peyronie's disease: evidence-based progress. | peyronie's disease (pd) is often physically and psychologically devastating for patients, and the goal of treatment is to improve symptoms and sexual function without adding treatment-related morbidity. the potential for treatment-related morbidity after more invasive interventions, e.g. surgery, creates a need for effective minimally invasive treatments. we critically examined the available literature using levels of evidence to determine the reported support for each treatment. most available ... | 2014 | 24447536 |
| functional outcome of collagenase injections compared with fasciectomy in treatment of dupuytren's contracture. | this study was designed to provide comparative information on the safety and efficacy of injection with collagenase clostridium histolyticum (cch) and fasciectomy for patients with dupuytren's contracture (dc). | 2013 | 24426958 |
| examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for dupuytren's disease. | this study examined the efficacy, complications, and contracture recurrence in patients who received injectable collagenase clostridium histolyticum (cch) for dupuytren's-induced metacarpophalangeal (mp) and proximal interphalangeal (pip) joint contractures. | 2013 | 24426932 |
| erosion/abrasion-preventing potential of naf and f/sn/chitosan toothpastes in dentine and impact of the organic matrix. | the study investigated the erosion/abrasion-preventing potential of experimental naf (1,400 ppm f(-)) and amine fluoride (amf)/naf/sncl2/chitosan (1,400 ppm f(-), 3,500 ppm sn(2+), 0.5% chitosan) toothpastes relative to placebo and snf2 gel (970 ppm f(-), 3,000 ppm sn(2+)), and the impact of the demineralised dentine matrix on toothpaste effects. the study was a cyclic erosion/intervention experiment (10 days). samples were stored in mineral salt solution either without or with collagenase (from ... | 2014 | 24401756 |
| pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. | the pharmacokinetics of a hybrid peptide consisting of the n-terminal biologically active region of human parathyroid hormone (pth) linked to a collagen-binding domain (cbd) were evaluated in female sprague-dawley rats. the peptide, pth-cbd, consists of the first 33 amino acids of pth linked as an extension of the amino acid chain to the cbd peptide derived from colh collagenase of clostridium histolyticum. serum concentrations arising from single dose administration by the subcutaneous and intr ... | 2014 | 24399637 |
| dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless study): 3-year data. | to evaluate long-term efficacy and safety of collagenase clostridium histolyticum (cch) after the third year of a 5-year nontreatment follow-up study, collagenase option for reduction of dupuytren long-term evaluation of safety study. | 2013 | 23200951 |
| retraction: late complications of clinical clostridium histolyticum collagenase use in dupuytren's disease. | | 2012 | 23144771 |
| the efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate dupuytren's contracture. | the efficacy and safety of collagenase clostridium histolyticum (cch) in patients with dupuytren's contracture (dc) was demonstrated in a program including two pivotal phase 3 clinical trials (cord i and ii) which included patients with a broad range of disease severity. this analysis assessed the efficacy and safety of cch in the subpopulation of dc patients with up to two joints affected and moderate disease according to british society of surgery of the hand classification. this was in suppor ... | 2014 | 24397625 |
| efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple dupuytren contractures. | to assess the safety and efficacy of 2 concurrent injections of collagenase clostridium histolyticum (cch) in the same hand to treat multiple dupuytren flexion contractures. | 2014 | 24315486 |
| re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. | | 2014 | 24289857 |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren contracture: report of 40 cases. | dupuytren's disease (dd) is a fibroproliferative pathology that affects the palmar aponeurosis causing the development of nodules and collagen cords and the progressive flexion of the fingers. the standard procedure is surgical fasciectomy, followed by high recurrence rates. collagenase clostridium histolyticum (cch) injection represents an innovative noninvasive approach to the treatment of dd. this prospective study was designed to examine the efficacy and safety of cch injection performed in ... | 2014 | 24254968 |
| re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies: m. gelbard, i. goldstein, w. j. hellstrom, c. g. mcmahon, t. smith, j. tursi, n. jones, g. j. kaufman and c. c. carson, iii j urol 2013; 190: 199-207. | | 2014 | 24239419 |
| [news in the treatment of dupuytren's disease: from surgery to collagenase's injection]. | dupuytren's disease is a benign fibromatosis affecting the palmar and digital fascia and causing flexion contracture of the affected fingers. up to date, this affection has no curative treatment available. the author is presenting an updated review of the therapeutic arsenal available for dupuytren's disease cords correction. open fasciectomy remains the "gold standard" surgical treatment of the disease but enzymatic treatment of the cords by injected collagenase clostridium histolyticum represe ... | 2013 | 24195241 |
| acceleration of bone formation during fracture healing by injectable collagen powder and human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase. | growth factor delivered with implantable biomaterials has been used to both accelerate and ensure healing of open fractures in human patients. however, a major limitation of implantable biomaterials is the requirement for open surgical placement. here, we developed an injectable collagen material-based bone formation system consisting of injectable collagen powder with fibril morphology and collagen triple helix conformation, and basic fibroblast growth factor (bfgf) fused to the collagen-bindin ... | 2014 | 24124060 |
| baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with peyronie's disease. | peyronie's disease (pd) is a localized penile collagen disorder of the tunica albuginea associated with significant physical deformity and psychological impairment. current understanding of pretreatment characteristics in patients with chronic pd is limited by small samples, varied quality of assessments, and the lack of a pd-specific, validated measure of the psychosexual impact of pd. | 2013 | 24112401 |
| isolated and spontaneous correction of proximal interphalangeal joint contractures in dupuytren's disease: an exploratory analysis of the efficacy and safety of collagenase clostridium histolyticum. | dupuytren's contractures affecting proximal interphalangeal (pip) joints are challenging to treat. we explored the effects of collagenase clostridium histolyticum (cch) on pip joint contractures after injection of an affected metacarpophalangeal (mp) joint in the same finger and after injection of an isolated pip joint contracture. | 2013 | 24092562 |
| [treatment of dupuytren's disease using collagenase from clostridium histolyticum]. | the collagenase from clostridium histolyticum is a new therapeutic option, and the first pharmacological one, in the treatment of dupuytren's disease. | 2013 | 24071041 |
| effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. | to evaluate the impact of early prebiotic and probiotic intervention on preterm infants' well-being, crying, growth, and microbiological programming. | 2013 | 23915796 |
| understanding the course of peyronie's disease. | to correct common misconceptions about peyronie's disease (pd) that present obstacles to early recognition and treatment. | 2013 | 23869679 |
| [treatment of dupuytren's contracture by collagenase injection]. | dupuytren's disease is a disorder of the palmar aponeurosis responsible for apparition of pathological collagen cords that will gradually lead to a digital retraction. these cords cause functional disability to the hand with a real handicap for the patient. no curative treatment exists currently in this disease. injections of collagenase from clostridium histolyticum cause lysis of the collagen present in the cords and cause an interruption of the palmar cord. it is a new treatment in the manage ... | 2013 | 23856551 |
| oceanirhabdus sediminicola gen. nov., sp. nov., an anaerobic bacterium isolated from sea sediment. | a novel anaerobic bacterium, designated nh-jn4(t) was isolated from a sediment sample collected in the south china sea. cells were gram-stain-positive, spore-forming, peritrichous and rod-shaped (0.5-1.2×2.2-7 µm). the temperature and ph ranges for growth were 22-42 °c and ph 6.0-8.5. optimal growth occurred at 34-38 °c and ph 6.5-7.0. the nacl concentration range for growth was 0.5-6 % (w/v) with an optimum of 2.5 %. catalase and oxidase were not produced. substrates which could be utilized wer ... | 2013 | 23811141 |
| correction of infraorbital dark circles using collagenase-digested fat cell grafts. | a number of factors, including visibility of the orbicularis oculi muscle through thin skin, can cause dark circles around the eyes. fat grafts have been used to augment the lower eyelid skin to correct dark circles, but irregularities caused by leaving visible lumps of the fat can occur. we used collagenase-digested fat cell grafts to correct these deformities. | 2013 | 23437990 |
| skin graft loss resulting from collagenase clostridium histolyticum treatment of dupuytren contracture: case report and review of the literature. | treatment of dupuytren disease with collagenase clostridium histolyticum is increasingly used among hand surgeons. although it is generally safe and efficacious, complications related to enzymatic fasciotomy occur. postapproval surveillance and communication among hand surgeons continues to refine the indications, contraindications, and complications recognized in the treatment of dupuytren disease with enzymatic therapy. major treatment-related adverse events previously reported include flexor ... | 2013 | 23391354 |
| bother and distress associated with peyronie's disease: validation of the peyronie's disease questionnaire. | we validated the peyronie's disease questionnaire (http://www.auxilium.com/pdq), a 15-question self-reported survey that measures the impact and severity of peyronie's disease symptoms in 3 domains, including 1) psychological and physical symptoms, 2) penile pain and 3) symptom bother. | 2013 | 23376705 |
| clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. | impress (investigation for maximal peyronie's reduction efficacy and safety studies) i and ii examined the clinical efficacy and safety of collagenase clostridium histolyticum intralesional injections in subjects with peyronie disease. co-primary outcomes in these identical phase 3 randomized, double-blind, placebo controlled studies included the percent change in the penile curvature abnormality and the change in the peyronie disease questionnaire symptom bother score from baseline to 52 weeks. | 2013 | 23376148 |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren contracture: short-term results from 2 open-label studies. | the joint i (united states) and joint ii (australia and europe) studies evaluated the efficacy and safety of collagenase clostridium histolyticum (cch) injection for the treatment of dupuytren contracture. | 2013 | 23218556 |
| discovery of a potent inhibitor class with high selectivity toward clostridial collagenases. | secreted virulence factors like bacterial collagenases are conceptually attractive targets for fighting microbial infections. however, previous attempts to develop potent compounds against these metalloproteases failed to achieve selectivity against human matrix metalloproteinases (mmps). using a surface plasmon resonance-based screening complemented with enzyme inhibition assays, we discovered an n-aryl mercaptoacetamide-based inhibitor scaffold that showed sub-micromolar affinities toward coll ... | 2017 | 28820255 |
| effect of cocoa's theobromine on intestinal microbiota of rats. | to establish the role of cocoa theobromine on gut microbiota composition and fermentation products after cocoa consumption in rats. | 2017 | 28605130 |
| structural comparison of colh and colg collagen-binding domains from clostridium histolyticum. | clostridium histolyticum secretes collagenases, colg and colh, that cause extensive tissue destruction in myonecrosis. the c-terminal collagen-binding domain (cbd) of collagenase is required for insoluble collagen fibril binding and subsequent collagenolysis. the high-resolution crystal structures of colg-cbd (s3b) and colh-cbd (s3) are reported in this paper. the new x-ray structure of s3 was solved at 2.0-å resolution (r = 17.4%; r(free) = 23.3%), while the resolution of the previously determi ... | 2013 | 23144249 |
| in vitro fermentation of grape seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups and phenolic metabolites. | with the aim of investigating the potential of flavan-3-ols to influence the growth of intestinal bacterial groups, we have carried out the in vitro fermentation, with human faecal microbiota, of two purified fractions from grape seed extract (gse): gse-m (70% monomers and 28% procyanidins) and gse-o (21% monomers and 78% procyanidins). samples were collected at 0, 5, 10, 24, 30 and 48 h of fermentation for bacterial enumeration by fluorescent in situ hybridization and for analysis of phenolic m ... | 2013 | 23121387 |
| acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase. | basic fibroblast growth factor 2 (bfgf) is a potent mitogen for mesenchymal cells, and the local application of recombinant bfgf accelerates bone union and defect repair. however, repeated dosing is required for sustained therapeutic effect as the efficacy of bfgf decreases rapidly following its diffusion from bone defect sites. here, we attempted to develop a collagen-based bone formation system using a fusion protein (collagen binding-bfgf, cb-bfgf) consisting of bfgf and the collagen-binding ... | 2014 | 23775724 |
| surgical findings in the treatment of dupuytren's disease after initial treatment with clostridial collagenase (xiaflex). | we investigated the difficulty of surgical fasciectomy after previous treatment with clostridial collagenase injection. the 35 clinicians who had participated in the initial trials of this injection were contacted via email. twenty-eight responded, nine of whom reported on 15 patients. most (seven of nine) felt there was no significant distortion of anatomy and rated the level of technical difficulty as equivalent to a primary dupuytren's fasciectomy at the observed degree of contracture (nine o ... | 2014 | 23649016 |
| solution structure of clostridial collagenase h and its calcium-dependent global conformation change. | collagenase h (colh) from clostridium histolyticum is a multimodular protein composed of a collagenase module (activator and peptidase domains), two polycystic kidney disease-like domains, and a collagen-binding domain. the interdomain conformation and its changes are very important for understanding the functions of colh. in this study, small angle x-ray scattering and limited proteolysis were employed to reveal the interdomain arrangement of colh in solution. the ab initio beads model indicate ... | 2013 | 23561530 |
| analysis of efficacy and safety of treatment with collagenase clostridium histolyticum among subgroups of patients with dupuytren contracture. | collagenase clostridium histolyticum (cch) injection is a nonoperative treatment of hand contractures from dupuytren disease. this study assessed the efficacy and safety of cch in several subgroups of patients with increased surgical risk.data were pooled from 3 randomized, placebo-controlled, double-blind trials. this analysis included 271 patients with metacarpophalangeal (n = 167) or proximal interphalangeal (n = 104) joint contractures greater than or equal to 20 degrees treated with cch (0. ... | 2014 | 23511746 |
| budget impact analysis in spanish patients with dupuytren's contracture: fasciectomy vs. collagenase clostridium histolyticum. | the aim of this study was to estimate the budget impact of collagenase clostridium histolyticum (cch) vs. fasciectomy (fsc) surgery for the treatment of dupuytren's disease (dd) in spain. a cost minimization analysis was adopted (effectiveness was assumed to be equivalent for both techniques). dd related costs were considered. cch costs (including drug, administration and visits) were obtained from clinical trials and a real-life study. fsc costs (including type of admission, visits, operating r ... | 2013 | 23507313 |
| in vitro study of novel collagenase (xiaflex®) on dupuytren's disease fibroblasts displays unique drug related properties. | dupuytren's disease (dd) is a benign, fibroproliferative disease of the palmar fascia, with excessive extracellular matrix (ecm) deposition and over-production of cytokines and growth factors, resulting in digital fixed flexion contractures limiting hand function and patient quality of life. surgical fasciectomy is the gold standard treatment but is invasive and has associated morbidity without limiting disease recurrence. injectable collagenase clostridium histolyticum (cch)--xiaflex®--is a nov ... | 2012 | 22384021 |
| assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase clostridium histolyticum antibodies in human sera obtained from patients with dupuytren's contracture. | collagenase clostridium histolyticum (cch) contains a fixed ratio of class i (aux-i) and class ii (aux-ii) collagenases and is used as treatment for dupuytren's contracture. these two zn-dependent enzymes, produced by the gram-positive bacterium clostridium histolyticum, are related functionally to matrix metalloproteinases (mmps) which, among other functions, degrade the extracellular matrix. since aux-i and aux-ii exhibit sequence similarities to human mmps, we assessed mmp-1 (interstitial col ... | 2012 | 22357647 |
| a new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. | the optimal enzyme blend that maximizes human islet yield for transplantation remains to be determined. in this study, we evaluated eight different enzyme combinations (ecs) in an attempt to improve islet yield. the ecs consisted of purified, intact or truncated class 1 (c1) and class 2 (c2) collagenases from clostridium histolyticum (ch), and neutral protease (np) from bacillus thermoproteolyticus rokko (thermolysin) or ch (chnp). | 2012 | 22318245 |
| in vitro fermentation of a red wine extract by human gut microbiota: changes in microbial groups and formation of phenolic metabolites. | an in vitro batch culture fermentation experiment was conducted with fecal inocula from three healthy volunteers in the presence and absence of a red wine extract. changes in main bacterial groups were determined by fish during a 48 h fermentation period. the catabolism of main flavonoids (i.e., flavan-3-ols and anthocyanins) and the formation of a wide a range of phenolic microbial metabolites were determined by a targeted uplc-pad-esi-tq ms method. statistical analysis revealed that catechol/p ... | 2012 | 22313337 |
| impact of protease inhibitors on dentin matrix degradation by collagenase. | this proof-of-concept study assessed whether the reduction of the degradation of the demineralized organic matrix (dom) by pre-treatment with protease inhibitors (pi) is effective against dentin matrix loss. bovine dentin slices were demineralized with 0.87 m citric acid, ph 2.3, for 36 hrs. in sequence, specimens were treated or not (ut, untreated) for 1 min with gels containing epigallocatechin 3-gallate (egcg, 400 µm), chlorhexidine (chx, 0.012%), feso(4) (1 mm), naf (1.23%), or no active com ... | 2012 | 23023765 |
| late complications of clinical clostridium histolyticum collagenase use in dupuytren's disease. | while dupuytren's disease can cause disabling contractures requiring open surgery, a less-invasive option using clostridium histolyticum collagenase (chc) via percutaneous injection was recently reported. a recent prospective, randomized trial demonstrated few complications during 90 days follow-up, however did not assess any longer term follow-up for these patients. long-term outcomes in this setting have not been adequately reported, and the current manuscript aims to identify late complicatio ... | 2012 | 22912868 |
| bacterial collagen-binding domain targets undertwisted regions of collagen. | clostridium histolyticum collagenase causes extensive degradation of collagen in connective tissue that results in gas gangrene. the c-terminal collagen-binding domain (cbd) of these enzymes is the minimal segment required to bind to a collagen fibril. cbd binds unidirectionally to the undertwisted c-terminus of triple helical collagen. here, we examine whether cbd could also target undertwisted regions even in the middle of the triple helix. collageneous peptides with an additional undertwisted ... | 2012 | 22898990 |
| clostridium histolyticum collagenase in the treatment of dupuytren's contracture. | dupuytren's disease is a common, costly and recurrent health issue. this review compares clostridium histolyticum collagenase with current operative treatments. collagenase management is an effective non-surgical alternative associated with lower risks of serious adverse events, but higher incidence of non-serious adverse events. | 2012 | 22875519 |
| development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (mmps) in human serum by antibodies against enzyme therapeutics. | this paper summarizes the development and validation of five enzyme activity methods to assess the specific inhibition of human endogenous matrix metalloproteinases mmp-1 (interstitial collagenase), mmp-2 (gelatinase a), mmp-3 (stromelysin 1), mmp-8 (collagenase 2) and mmp-13 (collagenase 3) by anti-collagenase clostridium histolyticum (cch) antibodies in human serum. these mmps are of interest since antibodies against a therapeutic enzyme may cross-react with, and inactivate, the mmps. the vali ... | 2012 | 22854133 |
| conformational dynamics accompanying the proteolytic degradation of trimeric collagen i by collagenases. | collagenases are the principal enzymes responsible for the degradation of collagens during embryonic development, wound healing, and cancer metastasis. however, the mechanism by which these enzymes disrupt the highly chemically and structurally stable collagen triple helix remains incompletely understood. we used a single-molecule magnetic tweezers assay to characterize the cleavage of heterotrimeric collagen i by both the human collagenase matrix metalloproteinase-1 (mmp-1) and collagenase from ... | 2012 | 22720833 |
| efficacy of collagenase in patients who did and did not have previous hand surgery for dupuytren's contracture. | collagenase clostridium histolyticum (cch) is a non-surgical, efficacious therapy for dupuytren's contracture (dc). this study evaluated the efficacy and safety of cch in patients with previous dc surgery. data from 12 cch clinical trials were pooled. at screening, patients provided details about the type/date of previous dc surgery. reviewers coded descriptions to the operated hand, finger, and joint. of 1082 patients, 422 (39%) had previous dc surgery. for these patients with previous surgery, ... | 2012 | 22670890 |
| investigation of the impact of feeding lactobacillus plantarum crl 1815 encapsulated in microbially derived polymers on the rat faecal microbiota. | the aim of this study was to evaluate the impact of the administration of microencapsulated lactobacillus plantarum crl 1815 with two combinations of microbially derived polysaccharides, xanthan : gellan gum (1%:0·75%) and jamilan : gellan gum (1%:1%), on the rat faecal microbiota. | 2012 | 22612542 |
| highly sensitive single-fibril erosion assay demonstrates mechanochemical switch in native collagen fibrils. | it has been established that the enzyme susceptibility of collagen, the predominant load-bearing protein in vertebrates, is altered by applied tension. however, whether tensile force increases or decreases the susceptibility to enzyme is a matter of contention. it is critical to establish a definitive understanding of the direction and magnitude of the force versus catalysis rate (k c ) relationship if we are to properly interpret connective tissue development, growth, remodeling, repair, and de ... | 2013 | 22584606 |
| multiple concurrent collagenase clostridium histolyticum injections to dupuytren's cords: an exploratory study. | dupuytren's contracture (dc) is a progressive fibroproliferative disorder characterized by development of nodules and collagen cords within the palmar fascia of the hand. collagenase clostridium histolyticum (cch) is currently approved in adults with dc for the nonsurgical treatment of a single palpable cord during a 30-day treatment cycle. this open-label pilot study was designed to examine the safety, efficacy, and multiple-dose pharmacokinetics of injecting two cords (affected joints) with mu ... | 2012 | 22540636 |
| collagenase inhibitors from viola yedoensis. | fractionation of acetone and methanol extracts of viola yedoensis, under the guidance of inhibition against clostridium histolyticum collagenase (chc), resulted in the isolation of esculetin (1) (ic(50) 12 μm) and scopoletin (2) (ic(50) 1.8 μm) as the active constituents, together with trans-p-coumaric acid (3), cis-p-coumaric acid (4), 3-o-β-d-glucosyl-7-o-α-l-rhamnosylkaempferol (5), rutin (6), isovitexin (7), isoorientin (8), vicenin-2 (9), isoscoparin (10), vanillic acid (11) and adenosine ( ... | 2013 | 22529049 |
| phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with peyronie disease. | collagenase clostridium histolyticum is an investigational nonsurgical treatment for peyronie disease. in this phase 2b, double-blind, randomized, placebo controlled study we determined the safety and efficacy of collagenase c. histolyticum and assessed a patient reported outcome questionnaire. | 2012 | 22503048 |
| recent surgical and medical advances in the treatment of dupuytren's disease - a systematic review of the literature. | dupuytren's disease (dd) is a type of fibromatosis which progressively results in the shortening and thickening of the fibrous tissue of the palmar fascia. this condition which predominantly affects white-northern europeans has been identified since 1614. dd can affect certain activities of daily living such as face washing, combing hair and putting hand in a glove. the origin of dupuytren's contracture is still unknown, but there are a number of treatments that doctors have come across througho ... | 2012 | 22431952 |
| factors associated with erectile dysfunction and the peyronie's disease questionnaire in patients with peyronie disease. | to elucidate patient characteristics that impact symptom-related bother and erectile function in patients with peyronie disease (pd). | 2017 | 28554517 |
| in vitro approaches to assess the effects of açai (euterpe oleracea) digestion on polyphenol availability and the subsequent impact on the faecal microbiota. | a considerable proportion of dietary plant-polyphenols reach the colon intact; determining the effects of these compounds on colon-health is of interest. we hypothesise that both fibre and plant polyphenols present in açai (euterpe oleracea) provide prebiotic and anti-genotoxic benefits in the colon. we investigated this hypothesis using a simulated in vitro gastrointestinal digestion of açai pulp, and a subsequent ph-controlled, anaerobic, batch-culture fermentation model reflective of the dist ... | 2017 | 28551224 |
| difference in success treating proximal interphalangeal and metacarpophalangeal joints with collagenase: results of 208 treatments. | dupuytren disease (dd) is a fibroproliferative disorder of the palmar fasciae causing extension deficit and impaired hand function. treatment with injection of collagenase clostridium histolyticum (cch) is a nonsurgical treatment method. the aim of this study was to evaluate the difference in efficiency and recurrence at 12-month follow-up when treating metacarpophalangeal (mp) and proximal interphalangeal (pip) joints with cch. none of the patients had received previous treatments of their cond ... | 2017 | 28507849 |
| safety profile of collagenase clostridium histolyticum stratified by degree of penile curvature in patients with peyronie disease. | to examine the safety of collagenase clostridium histolyticum (cch) in adult men with penile curvature deformity <30°. cch is indicated for treatment of peyronie disease in adult men with palpable plaque and a penile curvature deformity ≥30° at start of therapy; however, during treatment, patients may receive cch injections when penile curvature deformity is <30°. | 2017 | 28502596 |
| efficacy and safety of collagenase clostridium histolyticum for dupuytren disease nodules: a randomized controlled trial. | to determine the safety and efficacy of collagenase clostridium histolyticum (cch) injection for the treatment of palmar dupuytren disease nodules. | 2017 | 28854973 |
| collagenase treatment enhances proteomic coverage of low-abundance proteins in decellularized matrix bioscaffolds. | there is great interest in the application of advanced proteomic techniques to characterize decellularized tissues in order to develop a deeper understanding of the effects of the complex extracellular matrix (ecm) composition on the cellular response to these pro-regenerative bioscaffolds. however, the identification of proteins in ecm-derived bioscaffolds is hindered by the high abundance of collagen in the samples, which can interfere with the detection of lower-abundance constituents that ma ... | 2017 | 28829951 |
| re: clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for peyronie disease. | | 2017 | 28817884 |
| self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for peyronie disease. | to compare perceived meaningfulness early in the course of collagenase clostridium histolyticum (cch) with final outcomes to evaluate its use as a predictor of efficacy. | 2017 | 28483591 |
| basic fibroblast growth factor-anchored multilayered mesenchymal cell sheets accelerate periosteal bone formation. | cell-based regenerative therapy has the potential to repair bone injuries or large defects that are recalcitrant to conventional treatment methods, including drugs and surgery. here, we developed a multilayered cell-based bone formation system using cells coated with fibronectin-gelatin (fn-g) nanofilms. the multilayered mesenchymal cells (mlmcs) were formed after two days of culture and were shown to express higher levels of bmp-2 and vegf compared to monolayer cultures of mcs. the mlmcs were u ... | 2017 | 28761877 |
| recent pathophysiological aspects of peyronie's disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. | peyronie's disease (pd) is a chronic inflammation of tunica albuginea of the corpora cavernosa that causes an inelastic plaque resulting in penis deformation. although its etiology is not completely known, there is general consensus that pd is genetically transmitted and secondary to penile trauma. in recent years, numerous studies demonstrated the role played by oxidative stress in pd pathogenesis, and other studies have described successful use of antioxidants in pd treatment. oxidative stress ... | 2017 | 28744308 |
| complications following collagenase treatment for dupuytren contracture. | collagenase clostridium histolyticum (cch) injection and manipulation is a relatively new method for treating dupuytren contracture that is growing in popularity. although side effects such as swelling and ecchymosis are common, they are typically mild and self-limited. major complications are rare but have included flexor tendon rupture and complex regional pain syndrome. | 2017 | 28635316 |
| safety and effectiveness of collagenase clostridium histolyticum in the treatment of peyronie's disease using a new modified shortened protocol. | to evaluate the efficacy and safety of collagenase clostridium histolyticum (cch; xiapex(®) , xiaflex(®) ) in the treatment of peyronie's disease (pd) using a new modified treatment protocol that aims at reducing the number of injections needed and reducing patient visits, thus reducing the duration and cost of treatment. | 2017 | 28612401 |
| outcome of dupuytren contractures after collagenase clostridium histolyticum injection: a single-institution experience. | collagenase clostridium histolyticum (cch) injection is an alternative to surgery for patients with dupuytren disease (dd) of the metacarpophalangeal (mcp) and proximal interphalangeal (pip) joints. the success of surgical and nonsurgical treatment modalities for dd is reported to vary widely between 25% and 80% (j bone joint surg am. 1985;67:1439-1443; plast reconstr surg. 2007;120:44e-54e; j bone joint surg am. 2007;89:189-198; j hand surg am. 2011:36:936-942; j hand surg am. 1990;15:755-761; ... | 2017 | 28604542 |
| injectable collagenase versus percutaneous needle fasciotomy for dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. | collagenase clostridium histolyticum (cch) injection was introduced commercially as a treatment for dupuytren contracture following initial phase-3 investigations in 2009 with promising results. however, the efficacy of cch has not been prospectively investigated in a direct comparison to other active treatments of dupuytren contracture with more than 1-year follow-up, despite a wide and increasing clinical use. | 2017 | 28473158 |
| collagenase clostridium histolyticum in the treatment of urologic disease: current and future impact. | peyronie's disease (pd) is a connective tissue disorder resulting in the abnormal accumulation of type i to iii collagen, fibrin, and disorganized elastic fibers in the tunica albuginea of the penis. many medical and non-pharmacologic modalities have been used in the treatment of pd; however, these approaches have proved largely ineffective, with surgery being the only definitive treatment. intralesional injection of collagenase clostridium histolyticum (cch) has recently become the gold standar ... | 2017 | 28454897 |
| changes in the effects of peyronie's disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. | collagenase clostridium histolyticum (cch) intralesional injection was efficacious for the management of peyronie's disease (pd) in the double-blinded, randomized, placebo-controlled investigation for maximal peyronie's reduction efficacy and safety studies i and ii (impress i and ii). little is known about the consequences of pd or treatment on the sexual partners of affected men. | 2017 | 28395998 |